Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19

被引:3
|
作者
Galindo-Oseguera, Evelyn [1 ]
Pinto-Almazan, Rodolfo [2 ]
Arellano-Ramirez, Alfredo [3 ]
Gasca-Lopez, Gilberto Adrian [3 ]
Ocharan-Hernandez, Maria Esther [2 ]
Calzada-Mendoza, Claudia C. [2 ]
Castillo-Cruz, Juan [2 ]
Martinez-Herrera, Erick [2 ,4 ]
机构
[1] Inst Politecn Nacl, Escuela Super Med, Mexico City 11340, DF, Mexico
[2] Inst Politecn Nacl, Escuela Super Med, Secc Estudios Posgrad & Invest, Mexico City 11340, DF, Mexico
[3] Hosp Reg Alta Especial Ixtapaluca, Ixtapaluca 56530, Mexico
[4] SERGAS UVIGO, Efficiency Qual & Costs Hlth Serv Res Grp EFISALU, Galicia Sur Hlth Res Inst IIS Galicia Sur, Vigo 36213, Spain
关键词
SARS-CoV-2; COVID-19; risk factors; survival factors; mortality factors; OXYGEN-THERAPY; DISEASE;
D O I
10.3390/healthcare11070932
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
During the pandemic, some mortality-related factors were age, sex, comorbidities (obesity, diabetes mellitus, and hypertension), recovery time, hospitalizations, and biochemical markers. The present work aimed to identify the mortality and survival factors in adults with moderate and severe pneumonia due to COVID-19 during the first and second waves of the pandemic in Mexico at a third-level hospital (High-Specialty Regional Hospital of Ixtapaluca (HRAEI), Ixtapaluca, Estado de Mexico, Mexico). A database was generated using information from the electronic clinical records of patients hospitalized from December 2021 to August 2022. Survival analysis was performed associating age, sex, longer recovery times, and some drugs. The risk factors found were age in the patients between 40 and 60 years (OR = 1.70), male sex (OR = 1.53), the presence of comorbidities (OR = 1.66) and hypertension (OR = 2.19), work occupation (construction workers OR = 5.22, factory workers OR = 3.13, unemployed OR = 2.93), the prehospital use of metamizole sodium (OR = 2.17), cough (OR = 1.73), and in-hospital oxygen therapy (reservoir mask OR = 6.6). The survival factors found in this study were working in the healthcare field (OR = 0.26), the prehospital use of certain medications (paracetamol OR = 0.65, dexamethasone OR = 0.55, and azithromycin OR = 0.47), presenting ageusia (OR = 0.5) and hyporexia (OR = 0.34), and the time using in-hospital oxygen therapy (device 1 OR = 0.72). Prehospital treatment needs to be reevaluated as dexamethasone and azithromycin proved to be protective factors. Likewise, providing aggressive oxygen therapy during hospital admission decreased mortality risk.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Parameters of coagulation and platelet hyperreactivity reflect an increased mortality in patients with moderate to severe COVID-19
    Jakobs, K.
    Puccini, M.
    Reinshagen, L.
    Alsheikh, A. A.
    Friebel, J.
    Lanmdesser, U.
    Haghikia, A.
    Kraenkel, N.
    Rauch, U.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 2652 - 2652
  • [42] ICU Delirium Is Associated with Cardiovascular Burden and Higher Mortality in Patients with Severe COVID-19 Pneumonia
    Gutowski, Mateusz
    Klimkiewicz, Jakub
    Michalowski, Andrzej
    Ordak, Michal
    Mozanski, Marcin
    Lubas, Arkadiusz
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [43] Determinants of survival in patients on extracorporeal membrane oxygenation therapy due to severe covid-19
    Natanov, Ruslan
    Kunkel, Elena R.
    Wiesner, Olaf
    Haverich, Axel
    Wiegmann, Bettina
    Ruemke, Stefan
    Kuehn, Christian
    [J]. PERFUSION-UK, 2023, 38 (07): : 1393 - 1398
  • [44] Characteristics and results of a series of 59 patients with severe pneumonia due to COVID-19 admitted in the ICU
    Serrano-Martinez, J. L.
    Machado-Casas, J. F.
    Redondo-Orts, M.
    Manzano-Manzano, F.
    Castano-Perez, J.
    Perez-Villares, J. M.
    [J]. MEDICINA INTENSIVA, 2020, 44 (09) : 580 - 583
  • [45] Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients
    Aboelsaad, Iman
    Ashmawy, Rasha
    Mahrous, Doaa
    Sharaf, Sandy
    Aly, Shahinda
    Abdullatif, Sara
    Fakhry, Ayat
    Hassan, Basma
    Khamis, Dalia
    Aldakhs, Alaa
    Kamal, Ehab
    [J]. COVID, 2022, 2 (12): : 1758 - 1767
  • [46] Mortality and survival of COVID-19
    Sousa, G. J. B.
    Garces, T. S.
    Cestari, V. R. F.
    Florencio, R. S.
    Moreira, T. M. M.
    Pereira, M. L. D.
    [J]. EPIDEMIOLOGY AND INFECTION, 2020, 148
  • [47] REMDESIVIR FOR MODERATE-TO-SEVERE COVID-19 PNEUMONIA IN MAINTENANCE DIALYSIS PATIENTS: A RETROSPECTIVE COHORT STUDY
    Gutierrez, Stephanie
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I691 - I692
  • [48] Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial
    Zhuravel, Sergey, V
    Khmelnitskiy, Oleg K.
    Burlaka, Oleg O.
    Gritsan, Alexey, I
    Goloshchekin, Boris M.
    Kim, Seieun
    Hong, Ka Young
    [J]. ECLINICALMEDICINE, 2021, 41
  • [49] Mortality and Survival of Mechanically Ventilated Patients With COVID-19 Pneumonia in the US From NIS 2020
    Chkhikvadze, T.
    Meremikwu, K.
    Derevenskikh, G.
    Kryshtal, I.
    Kaliounji, A.
    Hakobyan, N.
    Inyang, L.
    Ankah, P.
    Aroshidze, B.
    Janssens, M.
    Sircy, A.
    Emasoga, G.
    Mohan, N.
    Uwagbale, E.
    Nemakallu, S.
    Ilerhunmwuwa, N.
    Shi, J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [50] Tocilizumab for severe COVID-19 pneumonia
    Mourad, Jean-Jacques
    Azria, Philippe
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (11): : E659 - E659